Denali expands antibody discovery deal with AbCellera

CEO of Denali Ryan Watts
Denali CEO Ryan Watts (Denali)

Denali Therapeutics has expanded its antibody discovery deal with AbCellera. The agreement tasks AbCellera with generating panels of antibodies for up to eight targets picked by Denali.

AbCellera wrapped up the first phase of its collaboration with Denali last year. That collaboration saw AbCellera search immune responses for naturally derived antibodies with specific binding properties against a neurodegenerative disease target of interest to Denali. 

With antibodies discovered by AbCellera now in Denali’s preclinical pipeline, the neurodegenerative disease specialist has firsthand experience of the merits of its partner’s platform and the antibodies it yields. That experience led to the new deal.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We continue to be impressed with the speed of discovery, the quality and the diversity of the antibodies AbCellera delivers,” Denali COO Alexander Schuth said in a statement.

In expanding the agreement, Denali has secured a source of antibodies against up to eight targets. Denali is paying a technology access fee and funding research, while committing to milestones and royalties, to secure the expanded relationship with AbCellera.

RELATED: Novartis inks 10-target antibody discovery deal with AbCellera

The expansion of the deal comes weeks after AbCellera struck a 10-target deal with Novartis. Talking at the time, AbCellera CEO Carl Hansen framed the Novartis agreement as an inflection point for his antibody R&D shop. Having made its name through single-target deals with GlaxoSmithKline, Merck and Teva, Hansen saw Novartis as the start of AbCellera’s move into “extended access” agreements.

Landing the eight-target Denali deal adds weight to the view that AbCellera is at an inflection point. To support its growing workload, AbCellera moved into a 22,000-square-foot lab last year and plans to grow its headcount from 72 to around 100 by the end of 2019.

For Denali, the AbCellera deal provides it with a source of antibodies as it seeks to stock its pipeline with neurodegenerative disease prospects. Denali’s lead drugs are now in the clinic but it also has a clutch of early-stage programs coming down the pipe.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.